http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016006577-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56541df79a26070c6c2c585b54af47c5
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
filingDate 2015-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d5ed618a9b2b6b0bcdfe118b23bf644
publicationDate 2016-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2016006577-A1
titleOfInvention Pharmaceutical composition
abstract A pharmaceutical composition for use in the treatment or prevention of disorders associated with ischemia, said composition comprising a mitochondrial damage-inhibiting agent, an anti-inflammatory agent, and biocompatible particles encapsulating either or both of the mitochondrial damage-inhibiting agent and the anti-inflammatory agent. The biocompatible particle may include a poly(lactide-glycolide) copolymer having a number average particle diameter of 2.5 to 1000 nm, or a polyethylene glycol-modified material derived therefrom.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018038267-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019102606-A1
priorityDate 2014-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014196281-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008026702-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2754
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394915
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399756
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6435378
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396371
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396372
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406346
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123915
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57417222
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54454

Total number of triples: 45.